Achillion Pharmaceuticals, Inc. Forecasted to Earn FY2018 Earnings of ($0.28) Per Share (ACHN)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Leerink Swann lowered their FY2018 earnings estimates for Achillion Pharmaceuticals in a note issued to investors on Thursday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($0.28) per share for the year, down from their prior estimate of ($0.20). Leerink Swann currently has a “Outperform” rating and a $6.00 target price on the stock.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. During the same quarter last year, the business posted ($0.13) EPS. COPYRIGHT VIOLATION WARNING: “Achillion Pharmaceuticals, Inc. Forecasted to Earn FY2018 Earnings of ($0.28) Per Share (ACHN)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/05/22/achillion-pharmaceuticals-inc-forecasted-to-earn-fy2018-earnings-of-0-28-per-share-achn.html.
Several other brokerages have also weighed in on ACHN. Ladenburg Thalmann Financial Services assumed coverage on Achillion Pharmaceuticals in a research report on Thursday, February 2nd. They issued a “buy” rating and a $10.00 target price on the stock. Maxim Group dropped their target price on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, April 25th. TheStreet lowered Achillion Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Wednesday, March 22nd. Zacks Investment Research lowered Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. Finally, Jefferies Group LLC reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $9.22.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 4.27 on Monday. The firm’s market cap is $583.81 million. Achillion Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $10.06. The firm’s 50-day moving average is $3.73 and its 200-day moving average is $4.11.
A number of large investors have recently modified their holdings of ACHN. Dimensional Fund Advisors LP raised its stake in shares of Achillion Pharmaceuticals by 224.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 405,802 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 280,620 shares in the last quarter. State Street Corp raised its stake in shares of Achillion Pharmaceuticals by 40.1% in the fourth quarter. State Street Corp now owns 5,121,160 shares of the biopharmaceutical company’s stock valued at $21,153,000 after buying an additional 1,465,723 shares in the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Achillion Pharmaceuticals by 1.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 50,102 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 699 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Achillion Pharmaceuticals during the fourth quarter worth approximately $162,000. Finally, Whalerock Point Partners LLC acquired a new position in shares of Achillion Pharmaceuticals during the third quarter worth approximately $264,000. 77.85% of the stock is currently owned by hedge funds and other institutional investors.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.